Ichnos Sciences welcomes collaboration with partners that have bold ideas and capabilities that complement and stretch our potential to shift progress, advance science, and deliver transformative medicines.
Oncology Pipeline and the BEAT® Platform Partnerships
Ichnos is committed to advancing our clinical-stage oncology portfolio and the next wave of discovery-stage assets. We are looking for partners who are interested in collaborating with us as we work to bring multispecific antibodies to patients with hematologic cancers and solid tumors.
Our BEAT® platform enables deep exploration of the bi/multispecific design space to optimize drug candidates and unlock new biology (e.g., T-cell, NK cells, macrophage engagers). Features include:
Heavy chain pairing technology
Heavy/light chain pairing technology using a common light chain
Proprietary tools for selection of high-quality antibodies (phage and mammalian display)
Effective target affinity maturation
Efficient purification aided by differential binding to Protein A, 95% yield in a single purification step
Flexible platform enables exploration of the full design space
Fc function activity can be modulated (T-cell: silent; non T-cell: active – enhanced)
Comprehensive screening capabilities enabling fast identification of leads with best functional activity and drug-like properties
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.
Concerning Your Privacy